These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 35961374)

  • 1. Systemic exposure to hydroxychloroquine and its relationship with outcome in severely ill COVID-19 patients in New York City.
    Lyashchenko AK; Yu Y; McMahon DJ; Bies R; Yin MT; Cremers S
    Br J Clin Pharmacol; 2023 Jan; 89(1):299-315. PubMed ID: 35961374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations.
    Steinbronn C; Chhonker YS; Stewart J; Leingang H; Heller KB; Krows ML; Paasche-Orlow M; Bershteyn A; Stankiewicz Karita HC; Agrawal V; Laufer M; Landovitz R; Wener M; Murry DJ; Johnston C; Barnabas RV; Arnold SLM
    Clin Transl Sci; 2023 Jul; 16(7):1243-1257. PubMed ID: 37118968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus.
    Yeon Lee J; Lee J; Ki Kwok S; Hyeon Ju J; Su Park K; Park SH
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):536-542. PubMed ID: 27390146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients.
    Sailler L; Puissant B; Méliani P; Castex JO; Saivin S; Adoue D; Fournie B; Arlet P; Montastruc JL; Lapeyre-Mestre M; Pourrat J; Blancher A
    Ann N Y Acad Sci; 2007 Jun; 1108():41-50. PubMed ID: 17893969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis.
    Munster T; Gibbs JP; Shen D; Baethge BA; Botstein GR; Caldwell J; Dietz F; Ettlinger R; Golden HE; Lindsley H; McLaughlin GE; Moreland LW; Roberts WN; Rooney TW; Rothschild B; Sack M; Sebba AI; Weisman M; Welch KE; Yocum D; Furst DE
    Arthritis Rheum; 2002 Jun; 46(6):1460-9. PubMed ID: 12115175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.
    Koh HM; Chong PF; Tan JN; Chidambaram SK; Chua HJ
    J Clin Pharm Ther; 2021 Jun; 46(3):800-806. PubMed ID: 33768612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of hydroxychloroquine in paediatric lupus: data from a novel, direct-to-family clinical trial.
    Balevic SJ; Randell R; Weiner D; Beard C; Schanberg LE; Hornik CP; Cohen-Wolkowiez M; Gonzalez D;
    Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36328395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus.
    Lee JY; Vinayagamoorthy N; Han K; Kwok SK; Ju JH; Park KS; Jung SH; Park SW; Chung YJ; Park SH
    Arthritis Rheumatol; 2016 Jan; 68(1):184-90. PubMed ID: 26316040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.
    Gasperetti A; Biffi M; Duru F; Schiavone M; Ziacchi M; Mitacchione G; Lavalle C; Saguner A; Lanfranchi A; Casalini G; Tocci M; Fabbricatore D; Salghetti F; Mariani MV; Busana M; Bellia A; Cogliati CB; Viale P; Antinori S; Galli M; Galiè N; Tondo C; Forleo GB
    Europace; 2020 Dec; 22(12):1855-1863. PubMed ID: 32971536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma.
    Sok V; Marzan F; Gingrich D; Aweeka F; Huang L
    PLoS One; 2021; 16(3):e0247356. PubMed ID: 33667247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China.
    Huang X; Shu Q; Luo X; Ge W; Xie H; Zhou Y
    Rheumatol Ther; 2023 Dec; 10(6):1597-1607. PubMed ID: 37755649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus.
    Mancuso S; Spinelli FR; Agati L; Ciardi MR; Garufi C; Natalucci F; Molteni E; Truglia S; Riccieri V; Priori R; Mastroianni CM; Conti F
    Clin Exp Rheumatol; 2022 May; 40(5):890-896. PubMed ID: 35383554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
    O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
    JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hydroxychloroquine treatment on QT interval.
    Hooks M; Bart B; Vardeny O; Westanmo A; Adabag S
    Heart Rhythm; 2020 Nov; 17(11):1930-1935. PubMed ID: 32610165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.
    Zahr N; Urien S; Llopis B; Pourcher V; Paccoud O; Bleibtreu A; Mayaux J; Gandjbakhch E; Hekimian G; Combes A; Benveniste O; Saadoun D; Allenbach Y; Pinna B; Cacoub P; Funck-Brentano C; Salem JE
    Therapie; 2021; 76(4):285-295. PubMed ID: 33558079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.
    Yu B; Li C; Chen P; Zhou N; Wang L; Li J; Jiang H; Wang DW
    Sci China Life Sci; 2020 Oct; 63(10):1515-1521. PubMed ID: 32418114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine-treated systemic lupus erythematosus patients.
    Belmont HM; Haj-Ali M
    Rheumatology (Oxford); 2022 Dec; 62(1):450-456. PubMed ID: 35426919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19.
    Ruiz S; Concordet D; Lanot T; Georges B; Goudy P; Baklouti S; Mané C; Losha E; Vinour H; Rousset D; Lavit M; Minville V; Conil JM; Gandia P
    Int J Antimicrob Agents; 2021 Feb; 57(2):106247. PubMed ID: 33259916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.